BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nelson-Sathi S, Umasankar PK, Sreekumar E, Nair RR, Joseph I, Nori SRC, Philip JS, Prasad R, Navyasree KV, Ramesh S, Pillai H, Ghosh S, Santosh Kumar TR, Pillai MR. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. BMC Mol Cell Biol 2022;23:2. [PMID: 34991443 DOI: 10.1186/s12860-021-00403-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yakoubi A, Dhafer CEB. Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. Plasmonics 2023;18:311-47. [PMID: 36588744 DOI: 10.1007/s11468-022-01754-0] [Reference Citation Analysis]
2 Dehkordi MF, Mafakher L, Samiee-rad F, Rahmani B. Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: A functional and structural impact.. [DOI: 10.21203/rs.3.rs-2154240/v1] [Reference Citation Analysis]
3 Prasad R, Ajith H, Kumar Chandrakumaran N, Dnyaneshwar Khangar P, Mohan A, Nelson-sathi S. In silico study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants. Journal of Biomolecular Structure and Dynamics 2022. [DOI: 10.1080/07391102.2022.2143426] [Reference Citation Analysis]
4 Almagro JC, Mellado-sánchez G, Pedraza-escalona M, Pérez-tapia SM. Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. IJMS 2022;23:9763. [DOI: 10.3390/ijms23179763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Roshdy WH, Khalifa MK, San JE, Tegally H, Wilkinson E, Showky S, Martin DP, Moir M, Naguib A, Elguindy N, Gomaa MR, Fahim M, Abu Elsood H, Mohsen A, Galal R, Hassany M, Lessells RJ, Al-karmalawy AA, El-shesheny R, Kandeil AM, Ali MA, de Oliveira T. SARS-CoV-2 Genetic Diversity and Lineage Dynamics in Egypt during the First 18 Months of the Pandemic. Viruses 2022;14:1878. [DOI: 10.3390/v14091878] [Reference Citation Analysis]
6 Saini S, Agarwal M, Pradhan A, Pareek S, Singh AK, Dhawan G, Dhawan U, Kumar Y. Exploring the role of framework mutations in enabling breadth of a cross-reactive antibody (CR3022) against the SARS-CoV-2 RBD and its variants of concern. J Biomol Struct Dyn 2022;:1-14. [PMID: 35098888 DOI: 10.1080/07391102.2022.2030800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]